Non Hodgkin's Lymphoma News and Research

RSS

The Non-Hodgkin lymphomas (NHLs) are a diverse group of hematologic cancers which encompass any lymphoma other than Hodgkin's Lymphoma.

Study provides detailed characterization of neurotoxicity arising from CD19 CAR T-cell therapy

New potential biomarkers and a novel algorithm could help identify patients at increased risk of suffering from severe neurotoxicity after receiving CD19 CAR T-cell therapy. The study extensively characterized common and occasionally fatal side effects of this immunotherapy.

12 Oct 2017

Tattoo ink from 15 years ago mimics lymph node cancer: Case study

A 30 year old Australian woman presented to the doctors with numerous small lumps under her arms for around two weeks. When one of the nodes were put under the microscope, the doctors found pigments from tattoo ink that she’d got 15 years back.

4 Oct 2017

FDA grants accelerated approval to new drug for treating relapsed follicular lymphoma

The U.S. Food and Drug Administration today granted accelerated approval to Aliqopa (copanlisib) for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments known as systemic therapies.

14 Sep 2017

Female cancer survivors have higher risks of poor pregnancy outcomes, study finds

An International Journal of Cancer study found that female survivors of certain types of cancer have higher risks of poor outcomes in pregnancies conceived after diagnosis than women without cancer.

12 Sep 2017

Study identifies late effects that may interfere with work status of young adult cancer survivors

Factors that limit the work ability of young adult cancer survivors are reported today at the ESMO 2017 Congress in Madrid.

11 Sep 2017

Plant virus-based system can be used to deliver anti-cancer drugs

An article published in Experimental Biology and Medicine (Volume 242, Issue 14, August 2017) reports that a plant virus-based system can be used to deliver anti-cancer drugs.

21 Aug 2017

FDA approves fixed dose combination chemotherapy for subtypes of AML that have poor survival outcomes

The U.S. Food and Drug Administration (FDA) yesterday approved Vyxeos - a fixed dose combination chemotherapy for the treatment of adults with two types of acute myeloid leukemia (AML). The types of AML that would be treated with Vyxeos include newly diagnosed therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC). Vyxeos is a fixed-combination of the chemotherapy drugs daunorubicin and cytarabine.

3 Aug 2017

Infographic displays facts and information about stem cells, cord blood

Over 40,000 people have successfully stored stem cells with Smart Cells, however the industry is still relatively unknown and often subject to misinformation. In a bid to increase awareness and understanding of stem cell collection at birth, Smart Cells have created an informative infographic.

17 Jul 2017

Cord-blood-derived natural killer cells can be modified to destroy B-cell cancers

Immune cells with a general knack for recognizing and killing many types of infected or abnormal cells also can be engineered to hunt down cells with specific targets on them to treat cancer, researchers at The University of Texas MD Anderson Cancer Center report in the journal Leukemia.

13 Jul 2017

Differential RNA splicing may play role in prostate cancer disparities in African-American men

A form of genetic variation, called differential RNA splicing, may have a role in tumor aggressiveness and drug resistance in African American men with prostate cancer.

30 Jun 2017

FDA authorizes marketing of test to aid in diagnoses of serious cancers

The U.S. Food and Drug Administration today allowed marketing of ClearLLab Reagents (T1, T2, B1, B2, M), the first agency authorized test for use with flow cytometry to aid in the detection of several leukemias and lymphomas, including chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN).

29 Jun 2017

Study finds steady decline in severe health problems for childhood cancer survivors

Treatments for childhood cancer are often intense and carry the risk of lifelong health problems for survivors. An analysis of 23,600 childhood cancer survivors in the Childhood Cancer Survivor Study (CCSS), funded by the National Institutes of Health, found that the rate of severe health problems occurring five or more years after diagnosis has declined over time.

5 Jun 2017

Study finds no clear benefit of stem-cell transplant for double-hit lymphoma patients in remission

Patients with double hit lymphoma (DHL) who undergo autologous stem-cell transplantation (autoSCT) after achieving remission are not more likely to remain in remission or live longer than patients who do not undergo autoSCT, according to a new analysis from the Perelman School of Medicine and the Abramson Cancer Center of the University of Pennsylvania.

15 May 2017

WHO to launch pilot project for prequalifying biosimilar cancer medicines

This year WHO will launch a pilot project for prequalifying biosimilar medicines, a step towards making some of the most expensive treatments for cancer more widely available in low- and middle-income countries.

8 May 2017

Researchers show how Epstein-Barr virus manages to persist inside immune system's B cells

Viruses are notorious for taking over their host's operations and using them to their own advantage. But few human viruses make themselves quite as cozy as the Epstein-Barr virus, which can be found in an estimated nine out of ten humans without causing any ill effects.

3 May 2017

Scientists announce ‘outstanding’ results of new blood cancer study

Scientists have described new results of a blood cancer study as 'outstanding' in tackling previously untreatable forms of chronic lymphocytic leukemia.

27 Apr 2017

Second cancers are far deadlier in younger people than older adults

Second cancers in children and adolescents and young adults are far deadlier than they are in older adults and may partially account for the relatively poor outcomes of cancer patients ages 15-39 overall, a new study by UC Davis researchers has found.

20 Apr 2017

Differences found in cancer occurrence within African and US born blacks

The cancer profile of African-born blacks differs from that of United States-born blacks and varies by region of birth, according to a new study. The study, appearing in CANCER, suggests differences in environmental, cultural, social, and genetic factors, and points to an opportunity to study the risk factors associated with the cancer burden in African-born blacks to help create targeted interventions.

14 Apr 2017

Number of HIV-positive cancer patients in the U.S. projected to decrease through 2030

As the population of people living with HIV in the United States ages, the burden of cancer for these patients is expected to shift away from cancers linked to AIDS and toward malignancies that affect the general population, according to a new study led by a University of North Carolina at Chapel Hill researcher.

5 Apr 2017

Investigational compound for treating indolent lymphomas shows positive results in phase II clinical study

Bayer today announced positive data on its investigational compound copanlisib, an intravenous pan-Class I phosphatidylinositol-3-kinase (PI3K) inhibitor with predominant inhibitory activity against PI3K-α and PI3K-δ isoforms.

31 Mar 2017